================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of earliest event reported: January 26, 2005
QLT INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
British Columbia, Canada 000-17082 N/A
- ---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
887 Great Northern Way, Vancouver, B.C. Canada, V5T 4T5
---------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(604) 707-7000
----------------------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On January 26, 2005, QLT Inc. reported that its marketing partner,
Sanofi-aventis, announced North American Eligard(R) sales of approximately 58
million euros for the year ended December 31, 2004. Total worldwide sales for
Eligard were approximately US$84 million.
The full text of the press release announcing such results is attached
hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference. Such information shall not be deemed "filed" for purposes
of Section 18 of the Securities and Exchange Act of 1934, as amended, and is not
incorporated by reference into any filing of the company, whether made before or
after the date hereof, regardless of any general incorporation language in such
filing.
ITEM 9.01 FINANCIAL STATEMENTS & EXHIBITS
c) EXHIBITS
Pursuant to the rules and regulations of the Securities and Exchange
Commission, the attached exhibit is deemed to have been furnished to, but not
filed with, the Securities and Exchange Commission:
Number Description
- ------ -----------
99.1 Press Release dated January 26, 2005 (Eligard Sales for FY 2004)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
QLT INC.
(Registrant)
By: /s/ Michael J. Doty
---------------------------------
Michael J. Doty
Senior Vice President and
Chief Financial Officer
Dated: January 26, 2005